Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | glutamate receptor NMDA | 0.0435 | 0.5683 | 0.5 |
Echinococcus multilocularis | glutamate receptor NMDA | 0.033 | 0.2499 | 0.2499 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0365 | 0.3578 | 0.3578 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0577 | 1 | 1 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0365 | 0.3578 | 0.1439 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | mm | In vitro antimicrobial activity of the compound against Escherichia coli was evaluated by measuring the diameter of zone of inhibition; NS denotes no significant inhibition | ChEMBL. | 15341971 |
Inhibition (functional) | mm | In vitro antifungal activity of the compound against Candida albicans was evaluated by measuring the diameter of zone of inhibition; NS denotes no significant inhibition | ChEMBL. | 15341971 |
Inhibition (functional) | NS 0 mm | In vitro antimicrobial activity of the compound against Staphylococcus aureus was evaluated by measuring the diameter of zone of inhibition; NS denotes no significant inhibition | ChEMBL. | 15341971 |
Inhibition (functional) | NS 0 mm | In vitro antimicrobial activity of the compound against Escherichia coli was evaluated by measuring the diameter of zone of inhibition; NS denotes no significant inhibition | ChEMBL. | 15341971 |
Inhibition (functional) | NS 0 mm | In vitro antimicrobial activity of the compound against Pseudomonas aeruginosa was evaluated by measuring the diameter of zone of inhibition; NS denotes no significant inhibition | ChEMBL. | 15341971 |
Inhibition (functional) | NS 0 mm | In vitro antifungal activity of the compound against Candida albicans was evaluated by measuring the diameter of zone of inhibition; NS denotes no significant inhibition | ChEMBL. | 15341971 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.